What was known before {#section21-2054358118799690}
=====================

Little is known about the incidence and distribution of biopsy-proven kidney diseases. Changes in the distribution of biopsy diagnoses over time may have significant implications for resource allocation and future research.

What this adds {#section22-2054358118799690}
==============

This population-based study characterizes patient demographics and the evolution of biopsy-based kidney disease diagnosis over time in Southern Alberta.

Introduction {#section23-2054358118799690}
============

Since its establishment as a key diagnostic tool, kidney biopsy has become widely regarded as the gold standard for classifying renal disease.^[@bibr1-2054358118799690][@bibr2-2054358118799690][@bibr3-2054358118799690][@bibr4-2054358118799690]-[@bibr5-2054358118799690]^ It is now a common procedure that informs both diagnosis and management of many kidney diseases. When biopsy occurs promptly, it can prevent or delay the course of progression to kidney failure with its associated costs, morbidity, and mortality.

Despite a recent trend toward the development of kidney biopsy registries, population-based data on clinical and histologic parameters at the time of kidney biopsy are scant. Until recently, these efforts have been limited to national or international referral center registries, which are subject to referral bias due to overrepresentation of rarer conditions.^[@bibr6-2054358118799690][@bibr7-2054358118799690][@bibr8-2054358118799690][@bibr9-2054358118799690][@bibr10-2054358118799690]-[@bibr11-2054358118799690]^ As distribution and incidence of these etiologies vary globally over time and may be highly affected by local standard practice patterns, population-based efforts are required to inform trends in disease spectrum and biopsy practices. These data can be used to inform health policies and resource allocation, refine pretest probabilities in clinical practice, and facilitate research collaborations.^[@bibr6-2054358118799690][@bibr7-2054358118799690][@bibr8-2054358118799690][@bibr9-2054358118799690][@bibr10-2054358118799690]-[@bibr11-2054358118799690]^

The recently developed Biobank for the Molecular Classification of Kidney Disease (BMCKD) provides a comprehensive registry to gain insight into biopsy patterns in a large Southern Alberta population. The aim of our retrospective study was to gather descriptive data to evaluate demographic characteristics and histopathologic diagnoses in a population-based cohort.

We sought to determine whether the population-standardized annual biopsy rate and incidence of selected diagnostic categories among first native kidney biopsies have changed over the last 3 decades in Southern Alberta. Given the rise in obesity, diabetes, and aging population with chronic kidney disease (CKD), we anticipated an increasing annual biopsy rate and changing distribution of disease to reflect our more elderly and comorbid patient population.

Methods {#section24-2054358118799690}
=======

Study Design and Eligibility Criteria {#section25-2054358118799690}
-------------------------------------

We used the BMCKD to conduct a retrospective population-based cohort study of renal biopsies performed in Southern Alberta between 1985 and 2015. Kidney biopsies were performed as clinically indicated by the nephrologist, in both inpatient and outpatient settings as a day procedure. If patients had undergone more than one biopsy, we included data from the first adequate sample. We also separately grouped normal samples and those considered insufficient to make a diagnosis.

Population and Sources {#section26-2054358118799690}
----------------------

The province of Alberta has the fastest growing population in Canada, totaling over 4.2 million people.^[@bibr12-2054358118799690]^ In Southern Alberta, which includes Calgary and the surrounding area, the processing of renal pathology is centralized and conducted at Calgary Laboratory Services (CLS), located at the Foothills Medical Centre, in collaboration with Alberta Health Services (AHS) and the University of Calgary's Department of Pathology and Laboratory Medicine (DPLM). The centralized organization of renal pathology services has enabled the assembly of a population-based cohort of adult and pediatric kidney biopsies performed in Southern Alberta. The BMCKD was established at the University of Calgary in 2015, in partnership with CLS, AHS, researchers, clinicians, and patients.^[@bibr13-2054358118799690]^ The banked materials include paraffin and frozen tissue blocks, plastic-embedded tissue blocks for light and electron microscopy, histopathology slides, detailed pathology reports, and electron microscopy images. We extracted data on demographic characteristics, including age and sex at biopsy, biopsy date, and diagnoses from the Biobank database. Currently, we do not have information on indications for biopsy or patient outcomes linked to the biopsy data.

Classification Approach {#section27-2054358118799690}
-----------------------

We considered native and transplant biopsies separately and categorized native histopathologic diagnoses into 7 groups: glomerular diseases, diabetic nephropathy, deposition diseases, tubulointerstitial diseases, vascular diseases, hereditary kidney diseases, and any conditions not accounted for in the above groupings. Inadequate samples were excluded, and normal results grouped separately. In the event that categories were unclear based on the diagnostic information provided, a nephrologist and pathologist adjudicated the discrepancy. For instance, primary glomerulonephritis (GN) took precedence if found in a patient with coexisting diabetes- or hypertension-related changes.

Glomerular diseases were subclassified into proliferative and nonproliferative types. The proliferative diseases were divided into 5 main categories: immune (including IgA nephropathy, post-infectious GN, lupus nephritis, membranoproliferative GN), pauci-immune, anti-GBM (glomerular basement membrane), GN with monoclonal Ig deposits, and C3 glomerulopathy, as well as proliferative GN that could not be further subclassified. We classified glomerular diseases according to the 2016 consensus report on pathologic classification, diagnosis, and reporting of GN.^[@bibr14-2054358118799690]^ Nonproliferative glomerular disease was separated into focal segmental glomerulosclerosis, minimal change disease, and membranous nephropathy. All other glomerular disease was included in a "not otherwise specified" group.

We reported diabetic nephropathy as a separate category. Deposition diseases were mainly amyloidosis. Tubulointerstitial diseases included acute tubular necrosis, interstitial nephritis, and other processes resulting in significant tubulointerstitial inflammation or damage. Vascular diseases were subgrouped into hypertensive pathologies as well as thrombotic microangiopathies. Alport, thin basement membrane, and polycystic kidney disease were classified as hereditary. Any conditions not accounted for in the above groupings were labeled as such.

Data Analysis {#section28-2054358118799690}
-------------

We used descriptive statistics to summarize age, sex, and histological diagnosis. Categorical values were expressed as absolute frequencies and percentages; age was summarized using mean and standard deviation. We summarized biopsy information as counts over person-time (rates). We obtained census information to standardize data according to the annual population in Southern Alberta. We represented rates as biopsies per 100 000 person-years over time in 5-year increments from 1985 to 2014 (periods A to F). We assumed a Poisson distribution to estimate measures of central tendency and variance of rates. Data were analyzed using the STATA statistical software package, version 13.1 (StataCorp LP, College Station, Texas).

Results {#section29-2054358118799690}
=======

During the study period, 7327 patients underwent a renal biopsy, and 6434 of their biopsies (58% male; mean age: 47.9 ± 19.8 years) were ultimately included in the analysis ([Figure 1](#fig1-2054358118799690){ref-type="fig"} shows the enrollment process).

![Study population.\
*Note.* From 1985 onward, the Biobank includes 6821 total renal biopsy specimens. This represents the first sample from each patient if multiple biopsies were done during this time frame. In all, 387 biopsies were inadequate or had no identifiable pathology. Thus, we analyzed 6434 samples in total.](10.1177_2054358118799690-fig1){#fig1-2054358118799690}

The population-standardized annual biopsy rate has increased from 10.8 biopsies per 100 000 persons per year (1985-1989) to 18.2 biopsies per 100 000 persons per year (2010-2014) ([Figure 2](#fig2-2054358118799690){ref-type="fig"}).

![Population-standardized annual biopsy rate.](10.1177_2054358118799690-fig2){#fig2-2054358118799690}

Biopsy samples tended to include older people in more recent years: mean age at the time of renal biopsy has risen from 42.5 ± 19 to 51.4 ± 16 years over that interval, with a larger proportion of people older than age 70 ([Figure 3](#fig3-2054358118799690){ref-type="fig"}). There was a wide variation in study population age and sex by disease category. Hereditary diseases tended to be found among the youngest patients whereas deposition diseases were most often found in older patients ([Figure 4](#fig4-2054358118799690){ref-type="fig"}).

![Proportion of renal biopsies performed on elderly patients over study period, by time period.](10.1177_2054358118799690-fig3){#fig3-2054358118799690}

![Age at time of biopsy according to diagnostic class.](10.1177_2054358118799690-fig4){#fig4-2054358118799690}

The population-adjusted rate of normal biopsies varied between 0.24 and 1.26 biopsies per 100 000 persons per year but this did not consistently increase over time. Overall, the most prevalent etiology was glomerular disease (n = 3754), followed by transplant (n = 836), vascular (n = 566), diabetic (n = 523), tubulointerstitial (n = 411), deposition (n = 149), other (n = 124), and hereditary (n = 71) ([Table 1](#table1-2054358118799690){ref-type="table"}).

###### 

Study Population Demographics and Distribution by Disease Category.

![](10.1177_2054358118799690-table1)

  Diagnostic categories         n (%)          Age at biopsy   Female (%)
  ----------------------------- -------------- --------------- ------------
  Glomerular diseases           3754 (58.35)   45.04 ± 20.27   43.77
  Diabetic nephropathy          523 (8.13)     57.59 ± 13.50   41.30
  Deposition diseases           149 (2.32)     62.06 ± 13.76   43.62
  Tubulointerstitial diseases   411 (6.39)     51.89 ± 20.70   43.07
  Vascular diseases             566 (8.80)     56.34 ± 18.15   36.75
  Hereditary diseases           71 (1.10)      21.77 ± 20.37   33.80
  Transplant biopsies           836 (12.99)    46.59 ± 15.90   37.80
  Other                         124 (1.93)     47.24 ± 21.60   38.71

During this period, glomerular diseases remained the most prevalent pathologic grouping, though their relative proportion of the total has decreased from 72.32% to 62.92% ([Table 2](#table2-2054358118799690){ref-type="table"}). There was an increasing representation of diabetic kidney disease from 3.69% to 16.18%, and tubulointerstitial diseases from 5.87% to 7.36%, as expected ([Table 2](#table2-2054358118799690){ref-type="table"} and [Figure 5](#fig5-2054358118799690){ref-type="fig"}).

###### 

The Relative Frequencies of Histopathologic Diagnoses in Native Renal Biopsies by Time Period.

![](10.1177_2054358118799690-table2)

  Category             1985-1989      1990-1994      1995-1999      2000-2004      2005-2009      2010-2014
  -------------------- -------------- -------------- -------------- -------------- -------------- --------------
  Glomerular           431 (72.32%)   434 (71.15%)   525 (72.02%)   739 (67.61%)   719 (63.63%)   906 (62.92%)
  Diabetic             22 (3.69%)     24 (3.93%)     39 (5.35%)     82 (7.50%)     123 (10.88%)   233 (16.18%)
  Deposition           13 (2.18%)     17 (2.79%)     17 (2.33%)     31 (2.84%)     29 (2.57%)     42 (2.92%)
  Tubulointerstitial   35 (5.87%)     36 (5.90%)     51 (7.00%)     80 (7.32%)     103 (9.12%)    106 (7.36%)
  Vascular             58 (9.73%)     59 (9.67%)     69 (9.47%)     135 (12.35%)   130 (11.50%)   115 (7.99%)
  Hereditary           11 (1.85%)     14 (2.30%)     8 (1.10%)      13 (1.19%)     9 (0.80%)      16 (1.11%)
  Other                26 (4.36%)     26 (4.26%)     20 (2.74%)     13 (1.19%)     17 (1.50%)     22 (1.53%)
  Total                596            610            729            1093           1130           1440

![The relative frequencies of histopathologic diagnoses by time period.](10.1177_2054358118799690-fig5){#fig5-2054358118799690}

Further analysis of the proliferative and nonproliferative glomerular diseases revealed a growing incidence of pauci-immune GN and focal segmental glomerulosclerosis (FSGS) ([Table 3](#table3-2054358118799690){ref-type="table"} and [Figure 6](#fig6-2054358118799690){ref-type="fig"}).

###### 

The Relative Frequencies of Glomerular Lesions by Time Period.

![](10.1177_2054358118799690-table3)

  --------------------------------------------------------------------------------------------
  Category             1985-1989   1990-1994   1995-1999   2000-2004   2005-2009   2010-2014
  -------------------- ----------- ----------- ----------- ----------- ----------- -----------
  Proliferative                                                                    

   Immune              166\        161\        224\        335\        340\        416\
                       (49.55%)    (43.28%)    (47.26%)    (50.53%)    (50.22%)    (49.00%)

   Pauci-immune        0           24\         35\         59\         80\         109\
                                   (6.45%)     (7.38%)     (8.90%)     (11.82%)    (12.84%)

   Anti-GBM            4\          6\          12\         8\          12\         11\
                       (1.19%)     (1.61%)     (2.53%)     (1.21%)     (1.77%)     (1.30%)

   Monoclonal Ig       7\          2\          4\          0           1\          4\
                       (2.09%)     (0.54%)     (0.84%)                 (0.15%)     (0.47%)

   C3 Glomerulopathy   0           1\          0           0           0           1\
                                   (0.27%)                                         (0.12%)

  Nonproliferative                                                                 

   FSGS                46\         60\         85\         106\        104\        152\
                       (13.73%)    (16.13%)    (17.93%)    (15.99%)    (15.36%)    (17.90%)

   MCD                 24\         37\         41\         59\         49\         58\
                       (7.16%)     (9.95%)     (8.65%)     (8.90%      (7.24%)     (6.83%)

   Membranous          88\         81\         73\         96\         91\         98\
                       (26.27%)    (21.77%)    (15.40%)    (14.48%)    (13.44%)    (11.54%)

  Total                335         372         474         663         677         849
  --------------------------------------------------------------------------------------------

*Note.* GBM = glomerular basement membrane; FSGS = focal segmental glomerulosclerosis; MCD = minimal change disease.

![The relative frequencies of proliferative and nonproliferative glomerular lesions by time period.\
*Note.* GN = glomerulonephritis; GBM = glomerular basement membrane; FSGS = focal segmental glomerulosclerosis; MCD = minimal change disease.](10.1177_2054358118799690-fig6){#fig6-2054358118799690}

Discussion {#section30-2054358118799690}
==========

This study is the first to characterize the evolution of renal biopsy trends over time in Canada. We are performing biopsies more frequently, which may reflect improved accessibility of the procedure^[@bibr15-2054358118799690],[@bibr16-2054358118799690]^ as well as changes in the clinical approach to CKDs, especially with the advent of new therapies. In our center, nephrologists performed renal biopsies until the mid-1990s, when interventional radiology began to provide this service. This change may have influenced the observed increased rates of kidney biopsy. We perform more renal biopsies annually compared with 30 years ago, even when this is adjusted for the rapid population growth of our province. Other similar studies from the United States have used referral center databases, which may influence the patient population included.^[@bibr10-2054358118799690]^ In contrast, the BMCKD reflects the nature of renal biopsy in Canada, which is universally accessible and without cost to the patient. Many studies throughout North America, Europe, and Asia focus on GN alone.^[@bibr6-2054358118799690][@bibr7-2054358118799690][@bibr8-2054358118799690][@bibr9-2054358118799690]-[@bibr10-2054358118799690]^ In one of the more comparable analyses from Denmark, the authors state their number of annual biopsies has remained relatively stable at 570, though this was not population-adjusted.^[@bibr11-2054358118799690]^

The average age at time of biopsy is also increasing, which likely reflects population aging as well as a growing proportion of complex elderly patients referred to nephrology care. In keeping with national trends, the proportion of elderly individuals in Alberta is rising, and we expect this will continue to impact the distribution of biopsy-based diagnoses. About 12% of our population was older than 65 years in 2016, but this is projected to rise to at least 19% over the next 25 years.^[@bibr17-2054358118799690]^

The incidence of diabetic nephropathy as diagnosed by biopsy has increased substantially over the observation period. It is unclear if this relates primarily to a changing incidence of this condition, a baseline population that has more preexisting diabetes, or a better appreciation for the potential of other kidney diseases to occur in a diabetic patient. Provincial data suggest the incident diabetes rate nearly doubled from 3 to 6 per 1000 between 1996 and 2008.^[@bibr18-2054358118799690]^ In years past, longstanding diabetics with proteinuric kidney disease were likely less often confirmed by biopsy. However, with easier access to the procedure, we have observed an increasing interest in pathologic confirmation, especially to rule out other coexisting conditions that may significantly alter clinical management.^[@bibr19-2054358118799690],[@bibr20-2054358118799690]^

Within the subgroups of proliferative and nonproliferative glomerular diseases, there appears to be a growing incidence of biopsy-proven pauci-immune GN and FSGS with a relatively decreased proportion accounted for by other conditions. In the case of FSGS, this may reflect a higher prevalence of risk factors including obesity in our patient population, as well as change in biopsy practice overall. Recent data show that 67% of Albertans are at least overweight, with 28% of those being obese, which is higher than the national average.^[@bibr21-2054358118799690]^

The demographics of our population have changed over time, which we have documented in our biopsy registry. From a resource utilization perspective, this information informs individual and regional nephrologist practice in a unique way. Aggressive diseases that require immediate treatment, such as lupus nephritis and ANCA (antineutrophil cytoplasmic antibody)-associated vasculitis, benefit from rapid biopsy by interventional radiology and processing by pathology. We advocate for these services. Future studies are needed to correlate clinical indications for biopsy, biopsy practices and diagnosis, and patient outcomes. As the use of similar databases becomes more widespread, there will be opportunities for multicenter collaboration and data linkages.

This study is limited by its retrospective design and the fact that renal biopsy may not provide complete information as to the etiology of a patient's kidney disease. Furthermore, as in the case of membranoproliferative GN, classification schemes and nomenclature have changed over time, so recently recognized conditions such as C3 glomerulopathy may have been misclassified in earlier data. Although it is considered the diagnostic gold standard, disease can be localized, and the biopsy may be subject to sampling error, which can affect all studies of this nature.^[@bibr22-2054358118799690]^ In addition, there was a changing group of pathologists and nephrologists over this period. Variations in interpretation and application of biopsy indications by physician may influence recorded prevalence of certain diagnoses. We did not audit biopsy results and independently confirm recorded diagnoses for this study. We do not yet have complete information on indications or patient outcomes linked to the database. Despite these limitations, this study provides important and novel information on the epidemiology of biopsy-proven kidney disease diagnosis.

Conclusion {#section31-2054358118799690}
==========

In this study, the incidence of performing renal biopsies has increased significantly over the past 30 years. The trend is toward performing more biopsies in older patients, who tend to be more comorbid and have patterns of renal disease consistent with this. We found an increasing proportion of diabetic nephropathy and tubulointerstitial diseases over time, which likely reflects changes in the prevalence of causative factors as well as local biopsy practices. Transplant patients account for a larger percentage of total annual biopsies in recent years.

These results have implications for nephrologists, as well as resource stewardship and associated costs. Future studies are needed to clarify biopsy indications, safety, and patient outcomes. While with the advent of renal biomarkers, this landscape may change significantly in coming years, renal biopsy still remains the most valuable means of accurately diagnosing kidney diseases.
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